



NATIONAL PATIENT ADVOCATE FOUNDATION

A National Network for Healthcare Reform

Nancy Davenport-Ennis
Chief Executive Officer

EXECUTIVE BOARD

Roy A. Beveridge, MD
Immediate Past Board President
Co-Director, Stem Cell Transplant Center
Inova Fairfax Hospital

William T. McGivney, PhD
Board President
Chief Executive Officer
National Comprehensive Cancer Network

Edward G. Connette, Esquire
Board Vice-President
Lesnes & Connette

John L. Murphy
Board Financial Officer
Partner QIAN Capital, LLC

Leo E. Sands
Board Financial Officer
Executive Vice President & Chief
Administrative Officer
U.S. Oncology

Christian Downs, MHA, JD
Board Financial Officer
Deputy Executive Director
Association of Community Cancer Centers

Leah Arnett, RN, BSN, CCM, CLNC
Board Secretary
Nursing Director, University Health Services
University of Texas at Austin

Bruce Avery, MD
Hematology-Oncology Knoxville

Richard D. Carter, Esquire
Carter & Coleman

John H. Ennis, Jr., Co-Founder
Executive Vice President

The Honorable Patrick Dougherty
Missouri State Senate

Dianne Lamb
Patient Advocate

The Honorable Phil Hamilton
Virginia House of Delegates

Sheldon Weinhaus, Esquire
Advisor of Counsel to the firm of Weinhaus,
Dobson, Goldberg & Moreland

SCIENTIFIC BOARD

Otis W. Brawley, MD
Professor, Emory School of Medicine
Emory University

Dennis A. Gastineau, MD
Director, Human Cell Therapy Laboratory
Divisions of Transfusion Medicine
and Hematology,
Mayo Clinic

Robert M. Rifkin, MD, FACP
Director, Rocky Mountain Blood
& Marrow Transplant Program
Rocky Mountain Cancer Centers

F. Marc Stewart, MD
Medical Director, SCCA
Professor of Medicine
University of Washington
Fred Hutchinson Cancer Research Center

Richard L. Theriault, DO, MBA
Professor of Medicine
MD Anderson Cancer Center

Lori Williams, RN, MSN, DSN®, OCN, AOCN
MD Anderson Cancer Center & University of
Texas Houston School of Nursing

HONORARY BOARD

The Honorable Mary T. Christian

Pearl Moore, RN, MN, FAAN
Chief Executive Officer
Oncology Nursing Society

Paula Trahan-Rieger
Director of International Affairs
American Society of Clinical Oncology

Doris Simonson

February 2007

RE: SF 134: Coverage for routine care costs associated with clinical trials

The National Patient Advocate Foundation (NPAF) is keenly interested in legislation such as SF 134, which requires insurers to cover routine care costs associated with clinical trials.

To ensure that the coverage applies equally to all situations in which individuals may be participants in clinical trials, we urge the legislation to include among entities that can approve a clinical trial “an Institutional Review Board (IRB) which oversees industry and community trials.” In addition, we urge that legislation regarding coverage for routine care costs include the following criteria:

- Requires coverage for all four phases of clinical trials for cancer
- Requires coverage for adults and children
- Requires coverage for out-of-state clinical trials

Participation in clinical trials is essential for the continued development of new medications to effectively treat and/or cure patients with chronic and life-threatening illnesses; unfortunately, only 5% of cancer patients participate in clinical trials. A significant barrier to clinical trial participation is lack of insurance coverage for routine care costs such as office visits, hospital stays, laboratory tests, or other services that would normally be covered if the patient were not enrolled in a clinical trial. This added financial burden can discourage patient participation and slow the development of new, innovative treatments.

Several states have passed legislation requiring insurance companies to cover routine care costs during clinical trials. As of the submission of this letter, the following states have taken action on this issue: Arizona, California, Connecticut, Georgia, Louisiana, Maine, Massachusetts, Michigan, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, Ohio, Tennessee, Vermont, Virginia, and West Virginia. For specific information about the legislative action taken in those states, visit the National Cancer Institute website at <http://www.cancer.gov/clinicaltrials/developments/laws-about-clinical-trial-costs>.

National Patient Advocate Foundation (NPAF) is dedicated to improving access to care through legislative and policy reform at both the state and federal levels. NPAF advocacy activities are influenced by the experience of the patients we serve through our companion organization, Patient Advocate Foundation (PAF). PAF provides case management services directly to patients at no charge to help resolve insurance, job retention, and/or debt crisis matters relative to a serious diagnosis. In 2006, over 6 million Americans contacted Patient Advocate Foundation with a request for assistance. We invite you to review the NPAF and PAF websites to learn more about both organizations: www.npaf.org and www.patientadvocate.org

On behalf of NPAF’s Wyoming Volunteer State Policy Liaisons Pam Hall and Anne Larsen, the NPAF Advocates Network volunteers in Wyoming, and NPAF’s State Government Affairs, thank you for your work to expand coverage for routine care costs associated with clinical trials. If we can be of assistance in this work, please don’t hesitate to contact your Wyoming NPAF State Policy Liaison or NPAF State Government Affairs at 866-706-4977.